# Fluxion Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fluxion-biosciences

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.fluxionbio.com
- Total disclosed funding: $7M
- Latest round: Series B (Oct 20, 2007)
- Investors on record: 4

## About

Fluxion Biosciences, Inc., based in the US, specializes in innovative cellular technologies that enhance cell viability and proliferation for diverse applications in research and biopharmaceuticals.Fluxion Biosciences, Inc. was founded in 2005 and is headquartered in San Francisco, US. The company focuses on developing advanced cellular technologies and has completed a total of 4 deals. In August 2023, Fluxion was acquired by Cell Microsystems, Inc., strengthening its position in the biotechnology sector. The company was previously funded by Kodiak Venture Partners and others, raising a total of USD 2.00 mn, with the most recent funding round amounting to USD 2.00 mn.Fluxion Biosciences offers a range of advanced cellular technologies, including the CellRaft AIR® System, which maintains cells in their optimal state for enhanced research outcomes. Their product lineup features BioFlux Systems for physiological shear flow, the CERO 3D Incubator & Bioreactor for precise 3D cell culture environments, and the CASY Cell Counter & Analyzer for rapid cell counting. Additionally, IonFlux Mercury systems enable automated electrophysiology, serving academic institutions and biopharmaceutical companies across North America, Europe, and parts of Asia.Fluxion generates revenue through direct sales of its proprietary cellular technologies to research institutions and pharmaceutical companies. Clients engage in purchasing agreements for products like the CellRaft AIR® System, with pricing that accommodates single and bundled purchases. The company also pursues partnerships with larger biopharmaceutical firms, enhancing their research capabilities through tailored solutions.In August 2023, Cell Microsystems, Inc. acquired Fluxion Biosciences Inc. to enhance its product offerings for researchers and life science professionals globally. Future plans include the development of new products aimed at expanding into broader markets. The recent acquisition will enable the combined resources to innovate and support these initiatives, facilitating growth in both existing and new geographical regions.

## Funding rounds

- Series B, Oct 20, 2007, $7M — Kodiak Venture Partners, Claremont Creek Ventures, Life Science Angels, Inc., North Bay Angels

## Investors

- Kodiak Venture Partners (https://capitalatlas.ai/funds/kodiak-venture-partners) — Series B
- Claremont Creek Ventures (https://capitalatlas.ai/funds/claremont-creek-ventures) — Series B
- Life Science Angels, Inc. — Series B
- North Bay Angels — Series B